Literature DB >> 32448971

National trends in the use of PSA, urinalysis, and digital rectal exam for evaluation of lower urinary tract symptoms in men.

James Doolin1, Zachary A Reese2, Kenneth J Mukamal1.   

Abstract

PURPOSE: The purpose of this study was to describe the practices of primary care physicians (PCPs) and urologists in their implementation of the 2010 American Urological Association (AUA) recommendations for the management of benign prostatic hyperplasia (BPH) in a nationally representative sample.
METHODS: Data collected from 2008 to 2015 in the National Ambulatory Medical Care Survey (NAMCS) were used. Men aged 45 and older who presented with either a new complaint or exacerbation of lower urinary tract symptoms (LUTS) were included. Primary outcomes were the prevalence and determinants of prostate-specific antigen (PSA) testing, urinalysis (UA), and digital rectal exam (DRE), as all three were included in the AUA guidelines during the time period studied. In logistic regression analyses weighted to reflect national estimates, potential determinants of adherence for each testing modality were examined.
RESULTS: Between 2008 and 2015, 878 visits met inclusion criteria, corresponding to 14,399,121 ambulatory visits for new or exacerbated LUTS. Weighted prevalence estimates were 24% for PSA testing (95% CI: 19-29%), 61% for urinalysis (95% CI: 56-66%), and 18% for DRE (95% CI: 15-23%). Age ≥ 75 years was associated with lower prevalence of testing for all three tests, and region was associated with different testing estimates for PSA and UA. Patients referred to urologists were more likely to receive a DRE, although overall rates of DRE decreased per additional year of data.
CONCLUSIONS: Adherence to AUA guidelines for evaluation of LUTS in ambulatory visits was low in a nationally representative sample of Americans, particularly for PSA testing and DRE, suggesting substantial discordance between guidelines at the time and practice patterns. Practice patterns also differed by age and region. These discrepancies encourage increased education of providers in the implementation of the guidelines, particularly since they have been updated recently.

Entities:  

Keywords:  Delivery of health care; Diagnostic techniques; Health care surveys; Lower urinary tract symptoms; PSA

Year:  2020        PMID: 32448971     DOI: 10.1007/s00345-020-03261-5

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  8 in total

Review 1.  Managing patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.

Authors:  Mary McNaughton-Collins; Michael J Barry
Journal:  Am J Med       Date:  2005-12       Impact factor: 4.965

2.  Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.

Authors:  Virginia A Moyer
Journal:  Ann Intern Med       Date:  2012-07-17       Impact factor: 25.391

3.  Prostate size, nocturia and the digital rectal examination: a cohort study of 30 500 men.

Authors:  Benjamin V Stone; Jonathan Shoag; Joshua A Halpern; Sameer Mittal; Patrick Lewicki; David M Golombos; Dina Bedretdinova; Bilal Chughtai; Christopher E Barbieri; Richard K Lee
Journal:  BJU Int       Date:  2016-08-23       Impact factor: 5.588

4.  A national benchmark for the initial assessment of men with LUTS: data from the 2010 Royal College of Physicians National Audit of Continence Care.

Authors:  W Gibson; D Harari; J Husk; D Lowe; A Wagg
Journal:  World J Urol       Date:  2015-10-14       Impact factor: 4.226

5.  Benign prostatic hyperplasia evaluation and management by urologists and primary care physicians: practice patterns from the observational BPH registry.

Authors:  John T Wei; Martin M Miner; William D Steers; Raymond C Rosen; Allen D Seftel; David J Pasta; Wendy J Carman; Claus G Roehrborn
Journal:  J Urol       Date:  2011-07-24       Impact factor: 7.450

6.  Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline Amendment 2019.

Authors:  Harris E Foster; Philipp Dahm; Tobias S Kohler; Lori B Lerner; J Kellogg Parsons; Timothy J Wilt; Kevin T McVary
Journal:  J Urol       Date:  2019-08-08       Impact factor: 7.450

7.  Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians.

Authors:  Amir Qaseem; Michael J Barry; Thomas D Denberg; Douglas K Owens; Paul Shekelle
Journal:  Ann Intern Med       Date:  2013-05-21       Impact factor: 25.391

Review 8.  Benign prostatic hyperplasia: epidemiology, economics and evaluation.

Authors:  Camille Vuichoud; Kevin R Loughlin
Journal:  Can J Urol       Date:  2015-10       Impact factor: 1.344

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.